Novel Alanine Transaminase Enzymes and Methods of Use

ABSTRACT

Novel alanine transaminase (ALT) polypeptides and the use thereof as a diagnostic marker to predict and monitor tissue damage and/or tissue malfunction. The ALT polypeptides are murine and/or  rattus  ALT polypeptides and said ALT polypeptides are used to detect, predict and/or determine hepatic processes of an animal, particularly mice and/or rats.

CROSS REFERENCE TO RELATED APPLICATION

This application claims priority from U.S. provisional patent application Ser. No. 60/563,389, filed on 19 Apr. 2004, and U.S. provisional patent application Ser. No. 60/588,126, filed on 15 Jul. 2004. The priority provisional patent applications are hereby incorporated by reference herein in their entirety and are made a part hereof, including but not limited to those portions which specifically appear hereinafter.

This work was supported in part by grant R03 DK60563-01 from the National Institutes of Health.

FIELD OF THE INVENTION

This invention relates to alanine transaminase (ALT) polypeptides and the use thereof as a diagnostic marker to predict and monitor tissue damage and/or tissue malfunction. More specifically, the ALT polypeptides are murine and/or rattus ALT polypeptides and said ALT polypeptides are used to detect, predict and/or determine hepatic processes of an animal, particularly mice and/or rats. The present invention additionally relates to assays for the ALT polypeptides to diagnose tissue damage and/or tissue malfunction having a range of etiologies that include but are not limited to hepatitis, nonalcoholic steatohepatitis (NASH), fatty liver, cirrhosis, and drug hepatotoxicity, and other disorders in muscle, brain, kidney, and adipose tissue, particularly in mice and/or rats.

BACKGROUND OF THE INVENTION

Alanine transaminase (ALT) [EC 2.6.1.2., also known as glutamate pyruvate transaminase (GPT) and alanine aminotransferase] is a pyridoxal enzyme catalyzing reversible transamination between alanine and 2-oxoglutarate to form pyruvate and glutamate. By mediating the conversion of these four major intermediate metabolites, ALT plays an important role in gluconeogenesis and amino acid metabolism. In muscle and certain other tissues, ALT degrades amino acids for fuel, and amino groups are collected from glutamate by transamination. ALT transfers the α-amino group from glutamate to pyruvate to form alanine, which is a major amino acid in blood during fasting. Alanine is taken up by the liver for generating glucose from pyruvate in a reverse ALT reaction, constituting the so-called alanine-glucose cycle. This cycle is also important during intensive exercise when skeletal muscles operate anaerobically, producing not only ammonia groups from protein breakdown but also large amounts of pyruvate from glycolysis.

ALT activities exist in many tissues, including liver, muscle, heart, kidney, and brain. Molecular cloning of the complementary DNAs (cDNAs) of two human ALT isoenzymes, hALT1 and hALT2 have been disclosed in International Publication WO 02/092768, herein fully incorporated by reference in its entirety. The independent DNA encoding for the two human ALT isoenzymes (gpt1 and gpt2, respectively) has been shown to be localized to separate chromosomes in humans, and that they have distinctive tissue distribution patterns, suggesting a tissue-dependent role for ALT isoenzymes.

Perhaps the most well-known aspect of ALT is that it is used clinically as an index of liver integrity or hepatocellular damage. Serum ALT activity is significantly elevated in a variety of liver damage conditions including viral infection, alcoholic steatosis, nonalcoholic steatohepatitis (NASH), and drug toxicity, although the underlying mechanism is generally not well understood. While low level of ALT is present in peripheral circulation because of normal cell turnover or release from nonvascular sources, the liver has been shown to contain the highest levels of ALT. The difference between ALT levels in liver and in blood has been shown to be about 2,000-3,000-fold. Hence, the increased ALT in serum, plasma, or blood is regarded as a marker of liver injury because of the “leakage” of hepatic ALT into the circulation. Usually, the nature of liver injury causes the blood ALT levels to vary greatly. Extremely high transaminase levels (greater than 8- to 10-fold normal) can indicate acute viral hepatitis and/or drug-induced hepatotoxicity. A mild chronic increase of serum ALT (2- to 8-fold) is generally a characteristic of chronic hepatitis, fatty liver, and/or steatosis. However, many details of the mechanism for the correlation of ALT levels with the etiology of liver damage remain to be understood.

Even though serum ALT is one of the most widely-used assays in clinical chemistry, there are serious deficiencies with the assay because it is an inadequate predictor in some cases. Recent studies have cast doubt on serum ALT assay's specificity for liver disease. Higher than normal ALT levels are frequently associated with other clinical conditions such as obesity, muscle disease, heart failure, hemochromatosis, Wilson's disease, αl-antitrypsin deficiency.

There is a need for improved ALT immunoassays that more accurately indicate and/or diagnose tissue injury and/or disease. There is a need for an ALT animal model for research and testing purposes. There is also a need for improved animal ALT immunoassays for use in, for example, drug testing and toxicology studies.

SUMMARY OF THE INVENTION

As discussed above, alanine aminotransferase (ALT) is a widely used index of liver integrity or hepatocellular damage in clinics as well as a key enzyme in intermediatary metabolism. Complementary DNAs of murine homologues of human alanine aminotransferase 1 and 2 (mALT1 and mALT2) and of rat homologues of human alanine aminotransferase 1 and 2 (rALT1 and rALT2) have been cloned.

The polypeptides of murine ALT1 (mALT1) and ALT2 (mALT2) of this invention share 87% and 93% identity, respectively, with their human counterparts at the amino acid level. The murine ALT genes of the two murine ALT isoenzymes localize to separate chromosomes, with the murine ALT1 gene (gpt1) on chromosome 15 and the murine ALT2 gene (gpt2) on chromosome 8. The murine gpt1 and gpt2 also differ in messenger RNA expression. The murine gpt1 is mainly expressed in liver, bowel, and white adipose tissue (WAT) and the murine gpt2 is highly expressed in muscle, liver, and white adipose tissue. Expression of recombinant murine ALT1 and murine ALT2 proteins in Escherichia coli (E. coli) produced functional enzymes that catalyze alanine transamination.

Rat ALT1 polypeptide consists of 496 amino acids and shares 97% and 88% identity to murine and human ALT1, respectively, at the amino acid level. Rat ALT2 polypeptide is composed of 522 amino acids and share 98% and 95% identity to murine and human ALT2, respectively, at the amino acid level. Rat ALT1 and rat ALT2 polypeptides have 68% sequence identity and 77% similarity. The genes of rat ALT1 and ALT2 reside on the chromosome 7 and 19, respectively. A sequence alignment of murine ALT1 and ALT2, human ALT1 and ALT2 and rat ALT1 and ALT2 is provided in FIG. 6.

The diagnostic value of murine ALT isoenzymes in liver disease was determined by an obese animal model. In fatty livers of obese mice, murine ALT2 gene expression is induced 2-fold, but murine ALT1 remains the same. Furthermore, in fatty liver, total hepatic murine ALT activity is elevated significantly by 30% whereas aspartate aminotransferase (AST) activity remains unchanged. Thus, murine ALT2 is responsible for the increased ALT activity in hepatic steatosis and allows for a murine ALT isoenzyme-specific assay having more diagnostic value than total ALT activity assays currently in clinical use. As many pharmaceutical companies do preclinical toxicology experiments in mice by measuring ALT as an indicator of liver toxicity, the murine isoenzyme-specific assays of this invention provide improved assays for assessing preclinical toxicity of new medications.

Another embodiment of the present invention is directed to antibodies, particularly anti-ALT1 antibodies and anti-ALT2 antibodies. In a specific embodiment, the antibody specifically binds to murine ALT1. In another specific embodiment, the antibody specifically binds to murine ALT2. In yet another specific embodiment, the antibody specifically binds to rat ALT1. In still yet another specific embodiment, the antibody specifically binds to rat ALT2.

It is an object of this invention to have a murine ALT polypeptide which has the amino acid sequence of SEQ ID NO:1 (murine ALT1) or an amino acid having about 95% homology thereto. In certain specific embodiments, the amino acid having about 95% homology to SEQ ID NO:1 is SEQ ID NO:6.

It is another object of this invention to have a murine ALT polypeptide which has an amino acid of SEQ ID NO:2 (murine ALT2) or an amino acid having about 95% homology thereto. In certain specific embodiments, the amino acid having about 95% homology to SEQ ID NO:2 is SEQ ID NO:5.

It is another object of this invention to have a polynucleotide which encodes for each of the murine ALT isoenzymes. It is a further object of this invention that the polynucleotide encodes the amino acid sequence of SEQ ID NO:1 and/or SEQ ID NO:2 or an amino acid sequence having about 95% homology to SEQ ID NO:1 and/or SEQ ID NO:2.

It is also further object of this invention that the polynucleotide sequence be the sequence of SEQ ID NO:3 or SEQ ID NO:4. In one embodiment in which the polynucleotide sequence is the polynucleotide sequence encoding for the homolog of SEQ ID NO:1 or SEQ ID NO:2, the polynucleotide sequences are SEQ ID NO:7 (rat ALT1) or SEQ ID NO:8 (rat ALT2).

It is another object of this invention to have a polynucleotide which encodes for each of the rat ALT isoenzymes. It is a further object of this invention that the polynucleotide encodes the amino acid sequence of SEQ ID NO:5 and/or SEQ ID NO:6 or an amino acid sequence having about 95% homology to SEQ ID NO:5 and/or SEQ ID NO:6. It is a further object of this invention that the polynucleotide sequence be the sequence of SEQ ID NO:7 or SEQ ID NO:8.

It is another object of this invention to have an antibody which binds specifically to one of the isoenzymes of ALT and not the other isoenzyme. For example, an antibody of one embodiment of this invention is specific for murine ALT2 and does not bind to murine ALT1. In an alternative embodiment, an antibody of the present invention is specific for rat ALT2 polypeptide and not rat ALT1 polypeptide. In embodiments where a mouse animal model is employed, the antibody of the present invention binds to the murine ALT2 sequence of SEQ ID NO:2 or an ALT2-specific fragment thereof or a homolog of SEQ ID NO:2, or, alternatively, to the protein encoded by the DNA sequence of SEQ ID NO:4 or a murine ALT2-specific fragment thereof.

In an alternative embodiment, such as for use in a rat animal model, an antibody of the present invention specifically binds a rat ALT2 amino acid sequence of SEQ ID NO:5 or a fragment or homolog thereof. In another embodiment, the antibody of the present invention specifically binds a rat ALT1 amino acid sequence of SEQ ID NO:6 or a fragment or homolog thereof.

It is an object of this invention to have an expression vector for each of the ALT isoenzymes. The expression vector can be a plasmid, cosmid, or other type of vector where the DNA sequence encoding for the ALT is operatively linked to expression sequences, such as a promoter. The DNA sequence for murine ALT can be the sequence of SEQ ID NO:3 and/or SEQ ID NO:4, or can be a sequence which encodes for the amino acid sequence of SEQ ID NO:1 and/or SEQ ID NO:2 or a homolog of SEQ ID NO:1 and/or SEQ ID NO:2. The DNA sequence for rat ALT can be the sequence of SEQ ID NO:7 (rALT1) and/or SEQ ID NO:8 (rALT2), or can be a sequence which encodes for the amino acid sequence of SEQ ID NO:5 and/or SEQ ID NO:6 or a homolog of SEQ ID NO:5 and/or SEQ ID NO:6.

It is an object of this invention to have a method for detecting the presence of ALT1 mRNA and/or ALT2 mRNA in a sample. It is a further object of this invention that the sample can be tissue or bodily fluids from a mouse and/or rat. It is a further object of this invention that a polynucleotide probe be used to detect the presence of the ALT1 mRNA and/or the ALT2 mRNA in a sample.

It is an object of this invention to have a method to detect the presence of ALT1 protein and/or ALT2 protein in a sample. It is a further object of this invention that the sample can be tissue or bodily fluids from a mouse and/or a rat. It is another object of this invention that one uses antibodies (monoclonal or polyclonal) that bind specifically to ALT1 or that bind specifically to ALT2 to detect the respective protein. It is another object of this invention that the bodily fluids can be blood, serum, lymph, urine, sweat, mucus, sputum, saliva, semen, spinal fluid, interstitial fluid, synovial fluid, cerebrospinal fluid, gingival fluid, vaginal fluid, and pleural fluid. It is also an object of this invention that the tissue can be liver, brain, muscle, adipose tissue, and kidney.

It is another object of this invention to have a method for diagnosing or detecting injury or disease involving tissue which contains ALT2. It is a further object of this invention that the method involves using antibodies (polyclonal or monoclonal) that specifically bind to a ALT2 polypeptide of the present invention to measure the level of ALT2 in bodily fluids from the animal. It is another object of this invention to use antibodies (polyclonal or monoclonal) that specifically bind to ALT1 to measure the level of ALT1 in bodily fluids from the animal and then to compare the level of ALT2 to ALT1. When the level of ALT2 is sufficiently higher than the level of ALT1 or the level of ALT2 falls within a pre-determined range, then the animal is diagnosed with a specific disease or injury. It is another object of this invention that the bodily fluids can be blood, serum, lymph, urine, sweat, mucus, sputum, saliva, semen, spinal fluid, interstitial fluid, synovial fluid, cerebrospinal fluid, gingival fluid, vaginal fluid, and pleural fluid. Furthermore, the tissue can be liver, brain, muscle, adipose tissue (white adipose tissue “WAT” or brown adipose tissue “BAT”), and kidney.

It is an object of this invention to have a kit useful in diagnosing damage or disease in tissue containing ALT. This kit has a measurer of ALT, either ALT1 or ALT2, levels in a sample of bodily fluids and an indicator for determining if amount of ALT measured by the ALT measurer falls in a range associated with damage or a specific disease in the ALT containing tissue. It is further object of this invention that the kit may also contain a measurer for both ALT1 and ALT2 levels in a sample of bodily fluids and an indicator for determining if amount of each of ALT1 and ALT2 measured by the measurer(s) falls in a range associated with damage or a specific disease in the ALT containing tissue. The ALT1 measurer and the ALT2 measurer can be a biologic assay, an antibody-based assay, an enzyme linked immunosorbent assay, a Western blot, a rapid immunoassay, a radioimmunoassay, and combinations thereof.

It is another object of this invention to have a diagnostic kit useful for diagnosing damage or disease to ALT1 containing tissue and/or ALT2 containing tissue. This diagnostic kit can contain ALT1 specific antibodies (polyclonal or monoclonal), immunoassay reagents, and a positive and negative control. This kit can also have ALT2 specific antibodies (polyclonal or monoclonal). This kit includes a means for determining if a measurement of ALT1 and/or ALT2 indicates a diagnosis of damage or disease in ALT1 containing tissue and/or ALT2 containing tissue. The kit can also have instructions indicating when a level of ALT1 and/or ALT2 is indicative for diagnosis of damage or disease in tissue containing ALT1 or ALT2.

It is still another object of this invention to have a kit useful in determining when there are altered levels of ALT2 in bodily fluids (altered can be higher than normal or lower than normal). This kit can have a measurer of ALT2 levels in a bodily fluids sample and an indicator for determining if the ALT2 level measured falls in a range associated with a specific condition. It is a further object of this invention that the kit can determine when there are altered levels of ALT1 in bodily fluids (altered can be higher than normal or lower than normal). This kit can also have a measurer of ALT1 levels in a bodily fluids sample and another indicator for determining if the ALT1 level measured falls in a range associated with a specific condition. Furthermore, this kit can have a third indicator for comparing the values of ALT1 and ALT2 and determining if the levels of ALT1 and ALT2 fall in a range associated with a specific condition. The measurer of this kit can be selected from one or more of the following: a biologic assay, an antibody-based assay, an enzyme linked immunosorbent assay, a Western blot, a rapid immunoassay, a radioimmunoassay, and combinations thereof.

It is an object of this invention to have a method for producing a ALT polypeptide of the present invention. The ALT produced can be the same as the amino acid sequences of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:5 or SEQ ID NO:6, or a homolog, fragment, or variant thereof. This method involves cloning the DNA encoding for ALT in an expression vector, introducing the expression vector into a host cell to produce a recombinant host cell, and subjecting to the recombinant host cell to conditions such that ALT is expressed. It is a further object of this invention that the ALT expressed can be isolated and purified. The DNA sequence placed in the plasmid can be the nucleic acid sequence of SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:7 or SEQ ID NO:8, or a nucleic acid sequence which encodes for a variant, homolog, or fragment of murine ALT1 or murine ALT2. Alternatively, the DNA sequence inserted into the plasmid may be a nucleic acid sequence which hybridizes, such as, for example, under conditions of high stringency, to a nucleic acid encoding a polypeptide of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:5 or SEQ ID NO:6. In a specific embodiment, the high stringency conditions include 0.1×SSC with 0.1% SDS wash buffer at hybridization temperature, such as, for example, at about 60, 61, 62, 63, 64, 65, 66, 67, or 68 degrees C.

It is another object of this invention to have a method for diagnosing a condition associated by altered levels of ALT2 and/or ALT1 in bodily fluids in an animal, particularly a mouse and/or a rat. This method involves contacting a sample of bodily fluids with at least one antibody which specifically binds to an ALT2 of the present invention, detecting the ALT2 antibody which is bound to ALT2, and comparing the amount of detected ALT2 antibody to a known quantity for an animal without the condition. In this method when the quantity of detected ALT2 antibody differs sufficiently from the known quantity from an animal without the condition, then it indicates that the animal has the condition. In addition, the method also can involve contacting the sample of bodily fluids with at least one antibody which specifically binds to ALT1, detecting the ALT1 antibody which is bound to ALT1, and comparing said amount of detected ALT 1 antibody to a known quantity for an animal without the condition. In this method, when the quantity of detected ALT1 antibody differs sufficiently from the known quantity from an animal without the condition, then it indicates that the animal has the condition. Furthermore, this method can also involve comparing the amount of ALT2 antibody detected to the total amount of antibody detected and/or to the amount of ALT1 antibody detect; and/or the amount of ALT1 antibody detected to the total amount of antibody detected and/or to the amount of ALT2 antibody detected. Again, the condition is indicated if the amount of ALT2 antibody detected when compared to the amount of ALT 1 antibody detected or the total amount of antibody detected falls within a certain range.

Again, the condition is indicated if the amount of ALT1 antibody detected when compared to the amount of ALT2 antibody detected or the total amount of antibody detected falls within a certain range. It is a further object of this invention that the bodily fluids for this method can be selected from the following group: blood, serum, lymph, urine, sweat, mucus, sputum, saliva, semen, spinal fluid, interstitial fluid, synovial fluid, cerebrospinal fluid, gingival fluid, vaginal fluid, and pleural fluid.

One embodiment of the invention is an isolated and purified murine ALT polypeptide comprising the amino acid sequence selected from a group including SEQ ID NO:1 and SEQ ID NO: 2. Another embodiment of the invention is an isolated and purified polynucleotide encoding for the murine ALT polypeptide. The isolated and purified polynucleotide of one embodiment comprises a polynucleotide sequence selected from a group including SEQ ID NO:3 and SEQ ID NO:4. The invention also includes an isolated and purified antibody which binds specifically to the murine ALT polypeptides of the present invention. The invention further includes an expression vector for murine ALT comprising the murine ALT polynucleotide sequence operatively linked to an expression sequence.

Another embodiment of the invention is an isolated and purified rat ALT polypeptide comprising the amino acid sequence selected from a group including SEQ ID NO:5 and SEQ ID NO: 6. Another embodiment of the invention is an isolated and purified polynucleotide encoding for the rat ALT polypeptide. The isolated and purified polynucleotide of one embodiment comprises a polynucleotide sequence of SEQ ID NO:7 or SEQ ID NO:8. The invention also includes an isolated and purified antibody which binds specifically to the rat ALT polypeptides of the present invention. The invention further includes an expression vector for rat ALT comprising the rat ALT polynucleotide sequence operatively linked to an expression sequence.

Another embodiment of the invention is a method of detecting in a sample the presence of mRNA, wherein the mRNA encodes for an ALT polypeptide of the present invention. The method comprises contacting the sample with a polynucleotide probe, wherein the polynucleotide probe is sufficient to specifically detect under stringent hybridization conditions the presence of the mRNA, and detecting the formation of a hybrid of the polynucleotide probe and the mRNA.

Another embodiment of the invention is a method of detecting an ALT polypeptide of the present invention in a sample, wherein the sample comprises a bodily fluid, the method comprising contacting a sample of the bodily fluids with at least one antibody that specifically binds to the ALT polypeptide and detecting the antibody which is bound to the ALT polypeptide in the sample.

Yet another embodiment of the invention is a method of diagnosing or detecting injury or disease involving tissue which contains an ALT polypeptide of the present invention in an animal suspected of having the injury or disease. The method comprises: contacting a sample of bodily fluids from the animal with at least one first antibody, wherein the first antibody specifically binds to an ALT1 polypeptide; detecting the first antibody which is bound to the ALT1 polypeptide in the sample; contacting the sample of bodily fluids with at least one second antibody wherein the second antibody specifically binds to an ALT2 polypeptide; detecting the second antibody which is bound to the ALT2 polypeptide in the sample; and comparing the amount of the ALT1 polypeptide bound to the first antibody and the amount of the ALT2 polypeptide bound to the second antibody; wherein when the amount of the bound ALT2 polypeptide is sufficiently higher than the amount of the bound ALT1 polypeptide, it indicates that the animal has a disease or injury affecting tissue containing ALT2. The sample of bodily fluids can comprise a fluid selected from a group comprising blood, serum, lymph, urine, sweat, mucus, sputum, saliva, semen, spinal fluid, interstitial fluid, synovial fluid, cerebrospinal fluid, gingival fluid, vaginal fluid, and pleural fluid. The tissue can be selected from a group comprising liver, brain, muscle, adipose tissue, and kidney.

Another embodiment of the invention is a method of diagnosing or detecting injury or disease involving tissue which contains an ALT polypeptide in an animal suspected of having the injury or disease. The method comprises: contacting a sample of bodily fluids from the animal suspected of having the injury or disease with at least one first antibody wherein the first antibody specifically binds to an ALT polypeptide; detecting the first antibody which is bound to the ALT polypeptide in the sample; and comparing the amount of the ALT polypeptide in the sample of bodily fluids to an amount of ALT in the bodily fluids of an animal known not to have injury or disease involving tissue which contains ALT polypeptide; wherein when the amount of ALT in the bodily fluids of the sample is higher than the amount of ALT polypeptide in the bodily fluids of the animal known not to have injury or disease it indicates that the animal suspected has a disease or injury affecting tissue containing ALT. The sample of bodily fluids can comprise a fluid selected from a group including blood, serum, lymph, urine, sweat, mucus, sputum, saliva, semen, spinal fluid, interstitial fluid, synovial fluid, cerebrospinal fluid, gingival fluid, vaginal fluid, and pleural fluid. The tissue can be selected from a group comprising liver, brain, muscle, adipose tissue, and kidney.

A further embodiment of the invention is a diagnostic kit for use in diagnosing damage or disease in tissue containing an ALT polypeptide of the present invention. The kit comprises a measurer for determining a measurement of an ALT polypeptide in a sample of bodily fluids and an indicator for determining if the measurement falls in a range associated with damage or disease in the tissue containing the ALT of the present invention. In one embodiment, the ALT polypeptide is murine ALT2 of SEQ ID NO:2 or an amino acid sequence having about 95% homology thereto. In certain embodiments, the homolog is an amino acid sequence of SEQ ID NO:5. In another embodiment, the ALT polypeptide is rat ALT2 of SEQ ID NO:5 or an amino acid sequence having about 95% homology thereto. The measurer can be selected from a group comprising a biologic assay, an antibody-based assay, an enzyme linked immunosorbent assay, a Western blot, a rapid immunoassay, a radioimmunoassay, and combinations thereof.

Another embodiment of the invention is a diagnostic kit for use in diagnosing damage or disease in tissue containing an ALT polypeptide of the present invention. The kit comprises: an aliquot of antibodies that bind specifically to an ALT polypeptide of the present invention; immunoassay reagents; and a control for determining if a measurement of an ALT polypeptide of the present invention indicates a diagnosis of damage or disease in tissue containing an ALT polypeptide of the present invention. The control comprises instructions indicating that an increase or decrease in the amount of the ALT polypeptide indicates a diagnosis for damage or disease in tissue containing the ALT polypeptide. In a further embodiment, the kit further comprises an aliquot of antibodies that bind specifically to ALT2 polypeptides of the present invention and a control for determining if a measurement of said ALT2 polypeptide indicates a diagnosis of damage or disease in tissue containing said ALT2 polypeptide. The control comprises instructions indicating that an increase or decrease in the amount of ALT2 indicates a diagnosis for damage or disease in tissue containing the ALT polypeptide.

Another embodiment of the invention is a diagnostic kit for use in a condition associated with altered levels of an ALT polypeptide 1 in bodily fluids. The kit comprises a measurer for determining a measurement of an ALT 1 polypeptide in a sample of bodily fluids and an indicator for determining if the measurement falls in a range associated with the condition.

Another embodiment of the invention is a diagnostic kit for use in a condition associated with altered levels of an ALT 2 in bodily fluids. The kit comprises a measurer for determining a measurement of an ALT 2 polypeptide in a sample of bodily fluids and an indicator for determining if the measurement falls in a range associated with the condition.

Another embodiment of the invention is a diagnostic kit for use in a condition associated with altered levels of at least one of an ALT 1 and an ALT2 in bodily fluids. The kit comprises: a measurer for determining a first measurement of an ALT 1 polypeptide in a sample of bodily fluids; a measurer for determining a second measurement of ALT2 polypeptide in the sample of bodily fluids; and an indicator for determining if the first and second measurements fall in a range associated with the condition.

Still another embodiment of the invention is method of diagnosing a condition associated by altered levels of an ALT 1 in bodily fluids in an animal suspected of having the condition. The method comprises: contacting a sample of bodily fluids from the animal with at least one antibody wherein the antibody specifically binds to an ALT 1 polypeptide; detecting the antibody which is bound to the ALT 1 polypeptide in the sample; and comparing the amount of the detected antibody to a known quantity for an animal without the condition; wherein if the quantity of the detected antibody differs sufficiently from the known quantity from an animal without the condition, indicates that the animal has the condition.

Another embodiment of the invention is a method of diagnosing a condition associated by altered levels of an ALT 2 in bodily fluids in an animal suspected of having the condition. The method comprises: contacting a sample of bodily fluids from the animal with at least one antibody wherein the antibody specifically binds to an ALT 2 polypeptide; detecting the antibody which is bound to the ALT 2 polypeptide in the sample; and comparing the amount of the detected antibody to a known quantity for an animal without the condition; wherein if the quantity of the detected antibody differs sufficiently from the known quantity from an animal without the condition, indicates that the animal has the condition.

The sample of bodily fluids for the above methods and/or kits can comprise a fluid selected from a group comprising of blood, serum, lymph, urine, sweat, mucus, sputum, saliva, semen, spinal fluid, interstitial fluid, synovial fluid, cerebrospinal fluid, gingival fluid, vaginal fluid, and pleural fluid.

The measurer for above methods and/or kits can be selected from the group comprising a biologic assay, an antibody-based assay, an enzyme linked immunosorbent assay, a Western blot, a rapid immunoassay, a radioimmunoassay, and combinations thereof.

Another embodiment of the invention is a method of producing an ALT polypeptide. The method comprises: providing an ALT polynucleotide sequence in an expression vector; introducing the expression vector into a host cell such that a recombinant host cell is produced; and subjecting to the recombinant host cell to conditions such that the ALT polypeptide is expressed. In one embodiment, the ALT polynucleotide sequence is selected from a group including SEQ ID NO:3 and SEQ ID NO:4. In another embodiment, the ALT polynucleotide sequence is selected from a group including SEQ ID NO:7 and SEQ ID NO:8.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-B are a comparison of the sequence of murine ALT isoenzymes (mALT1 and mALT2) of this invention and the polypeptide sequence of human ALT isoenzymes.

FIG. 1A is a comparison between murine ALT1 and human ALT1. FIG. 1B is a comparison between murine ALT2 and human ALT2. Peptide sequences are aligned using BESFIT from the GCG package and amino acids are numbered to the right of the sequence. Identical amino acids are denoted by a vertical bar, strongly similar amino acids by a colon (:), and weakly similar amino acids by a period (.).

FIG. 2 is Northern blots showing the expression of murine ALT mRNA. Blots from duplicate gels containing pooled total RNAs (15 μg/lane) from 3 to 4 mice were probed separately with ³²P-labeled murine ALT1 or ALT2 cDNAs. Hybridization signals were visualized by autoradiography. RNA loading from one of the duplicate gels is shown in the lower blot. The size of the mRNA transcripts is indicated in parentheses.

FIG. 3A is an electrophoresis gel where thirty microliters of E. coli extracts containing 100 to 150 μg of protein were analyzed on 4%-20% SDS-PAGE and stained with Coomassie Blue. Arrows indicate IPTG induced protein bands corresponding to mALT1 and mALT2.

FIG. 3B is a graph of ALT activity of soluble cell extracts of E. coli harboring plasmid pET28-mALT1 (ALT1), pET28-mALT2 (ALT2), or empty vector pET28 (control) after IPTG induction.

FIGS. 4A and 4B are Northern blots of total RNA extracted from fatty liver of obese (ob/ob) and lean (+/?) mice blotted with ³²P-labeled mALT1 or mALT2 DNA probe. FIG. 4C is a graph of murine ALT expression.

FIG. 5 is a graph of ALT and AST activities in obese (ob/ob) and lean (+/?) mice measured for their ALT and AST activities. Activities are expressed as mean ±SD (n=7). *P<0.05 is considered statistically significant.

FIG. 6 is a sequence alignment of ALT1 and ALT2 polypeptides from human, mouse and rat species. Highly conserved amino acids (≧90%) are in capital letters and less conserved (<90% and ≧50%) are in small letters. Symbol “!” is for any amino acids of I or V, “$” for L or M, “%” for F or Y, and “#” is for N, D, Q, E, B, or Z.

DEFINITIONS

Within the context of this specification, each term or phrase below will include the following meaning or meanings.

The terms “murine ALT polypeptide,” “murine ALT protein,” “murine ALT,” and “mALT” are interchangeable and generally refer to or include any and/or all murine ALT polypeptides or isoenzymes, including murine ALT1, murine ALT2, and any variant, homolog, or fragment of murine ALT1 or murine ALT2.

The terms “rat ALT polypeptide,” “rat ALT protein,” “rat ALT,” and “rALT” are interchangeable and generally refer to or include any and/or all rat (rattus) ALT polypeptides or isoenzymes, including rat ALT1, rat ALT2, and any variant, homolog, or fragment of rat ALT1 or rat ALT2.

The terms “protein” and “polypeptide” are used interchangeably in both singular and plural forms, as are the terms “nucleic acid” and “polynucleotide.”

These and additional terms may be defined with additional language in the remaining portions of the specification.

DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS

The present invention covers the nucleotide and amino acid sequences of murine ALT, antibodies specific to murine ALT, and the use of these polypeptides, polynucleotides, and antibodies to diagnose various diseases and conditions in tissue that produce murine ALT, such as fatty liver, and to differentially diagnose liver injury caused by fatty liver (liver steatosis) and by alcohol, trauma, infection, toxicity, and other causes of liver damage.

This invention also includes homologs and functional fragments of murine ALT polypeptides as well as expression vectors containing murine ALT polynucleotide sequences and recombinant host cells which contain an expression vector containing murine ALT polynucleotide sequences.

This invention also includes homologs and functional fragments of rat ALT polypeptides as well as expression vectors containing rat ALT polynucleotide sequences and recombinant host cells which contain an expression vector containing rat ALT polynucleotide sequences.

For this application, homology is often measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705 or the NCBI BLAST program). Such software matches similar sequences by assigning degrees of homology to various substitutions, deletions, substitutions, and other modifications.

The term “functional fragments” include those fragments of SEQ ID NO:1 and/or SEQ ID NO:2 and/or SEQ ID NO:5 and/or SEQ ID NO:6 and/or a polypeptide having about 95% sequence identity to that of the SEQ ID NO:1 and/or SEQ ID NO:2 and/or SEQ ID NO:5 and/or SEQ ID NO:6 and that retains the function, activity, or immunobiological properties of said ALT polypeptide. One of skill in the art can screen for the functionality of a fragment by using the examples provided herein, where full length ALT1 and ALT2 are described. By “substantially identical” is also meant an amino acid sequence which differs only by conservative amino acid substitutions, for example, substitution of one amino acid for another of the same class (e.g., valine for glycine, arginine for lysine, etc.) or by one or more non-conservative substitutions, deletions, or insertions located at positions of the amino acid sequence which do not destroy the function of the protein assayed (e.g., as described herein). Preferably, such a sequence is at least 85%, and more preferably from 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, to 100% homologous at the amino acid level to SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:5 or SEQ ID NO:6.

Functional Equivalence

Modification and changes may be made in the structure of the peptides of the present invention and DNA segments which encode them and still obtain a functional molecule that encodes a protein or peptide with desirable characteristics. The following is a discussion based upon changing the amino acids of a protein to create an equivalent, or even an improved, second-generation molecule. The amino acid changes may be achieved by changing the codons of the RNA sequence, according to the following codon table:

TABLE 1 Amino Acids Codons Alanine Ala A GCA GCC GCG GCU Cysteine Cys C UGC UGU Aspartic acid Asp D GAG GAU Glutamic acid Glu E GAA GAG Phenylalanine Phe F UUC UUU Glycine Gly G GGA GGC GGG GGU Histidine His H CAC CAU Isoleucine Ile I AUA AUC AUU Lysine Lys K AAA AAG Leucine Leu L UUA UUG CUA CUC CUG CUU Methionine Met M AUG Asparagine Asn N AAC AAU Proline Pro P CCA CCC CCG CCU Glutamine Gln Q CAA CAG Arginine Arg R AGA AGG CGA CGC CGG CGU Serine Ser S AGC AGU UCA UCC UCG UCU Threonine Thr T ACA ACC ACG ACU Valine Val V GUA GUC GUG GUU Tryptophan Trp W UGG Tyrosine Tyr Y UAC UAU

For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence, and, of course, its underlying DNA coding sequence, and messenger RNA sequence, and nevertheless obtain a protein with like properties. It is thus contemplated by the inventors that various changes may be made in the peptide sequences of the disclosed compositions, or corresponding DNA or RNA sequences which encode said peptides without appreciable loss of their biological utility or activity.

In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, 1982, incorporate herein by reference). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like.

Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics (Kyte and Doolittle, 1982), these are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (−0.4); threonine (−0.7); serine (−0.8); tryptophan (−0.9); tyrosine (−1.3); proline (−1.6); histidine (−3.2); glutamate (−3.5); glutamine (−3.5); aspartate (−3.5); asparagine (−3.5); lysine (−3.9); and arginine (4.5).

It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydropathic index or score and still result in a protein with similar biological activity, i.e., still obtain a biological functionally equivalent protein. In making such changes, the substitution of amino acids whose hydropathic indices are within .+−.2 is preferred, those which are within .+-.1 are particularly preferred, and those within .+−0.05 are even more particularly preferred.

It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Pat. No. 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein. As detailed in U.S. Pat. No. 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0.+−.1); glutamate (+3.0.+−.1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (−0.4); proline (−0.5.+−.1); alanine (−0.5); histidine (−0.5); cysteine (−1.0); methionine (−1.3); valine (−1.5); leucine (−1.8); isoleucine (−1.8); tyrosine (−2.3); phenylalanine (−2.5); tryptophan (−3.4).

It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity values are within .+−.2 is preferred, those which are within .+−.1 are particularly preferred, and those within .+-.0.5 are even more particularly preferred.

As outlined above, amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions which take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

It will also be understood that amino acid sequences may include additional residues, such as additional N- or C-terminal amino acids and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth above, including the maintenance of biological protein activity where protein expression is concerned. The addition of terminal sequences particularly applies to sequences, which may, for example, include various unnaturally occurring amino acid sequences flanking either of the N- or C-termini to allow for facile covalent linkage to another molecule, i.e., a reporter molecule.

In non-limiting examples, the homolog may include a substitution in SEQ ID NO:1 of C56R, F109L, D126N, R133K, I152V, P158L, Q165R, A200S, R204H, A05T, A222T, D227G, R249H, C253G, R258H, V263A, E291K, G293R, M297L, A328S(*), V339T, E352A, M387L, T393A, S395T, K400A, R406K, E408A, R421S, Q434R, L439P, K440R, Q443E, D447E(*), C459R, Q477R, M491L, V496L(*), R502S(*), H503R, H510L or a combination thereof.

In a non-limiting example, the homolog may include a substitution in SEQ ID NO:6 of C56R, F109L, D126N, R133K, I152V, P158L, Q165R, S200A, R204H, A205T, A222T, D227G, R249H, C253G, R258H, V263A, K291E, G293R, M297L, S328A, V339T, E352A, M387L, T393A, S395T, K400A, R406K, E408A, R421S, Q434R, L439P, K440R, Q443E, E447D, C459R, Q477R, M491L, L496V, S502R, H503R, H510L or a combination thereof.

In a non-limiting example, the homolog may include a substitution in SEQ ID NO:5 of H24Q, D45E, M77L, H99Q, N123D, L1961, 1228V, D245N, L251V, R252Q, Q253E, Q321E, P326H, V392E, S407F, Q430H, L445F, S456A, K458Q, E501D, H508Q, L515I, K516N, K520Q, S522A or a combination thereof.

In a non-limiting example, the homolog may include a substitution in SEQ ID NO:2 of H24Q, D45E, M77L, H99Q, N123D, L196I, V2281, D245N, L251V, R252Q, Q253E, Q321E, H326P, E392V, F407S, Q430H, L445F, S456A, K458Q, D501E, H508Q, L515I, K516N, Q520K, S522A or a combination thereof.

By a “substantially pure polypeptide” is meant a ALT polypeptide that has been separated from components that naturally accompany it. Typically, the polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and other naturally occurring molecules with which it is typically associated. Preferably, the preparation is at least 75%, 80%, 90%, 95%, and most preferably at least 99%, by weight, an ALT polypeptide. A substantially pure ALT polypeptide can be obtained, for example, by extraction from a natural source; by expression of a recombinant nucleic acid encoding the desired ALT polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis.

A protein is substantially free of naturally associated components when it is separated from those contaminants that accompany it in its natural state. Thus, a protein that is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates is substantially free from its naturally associated components. Accordingly, substantially pure polypeptides include those derived from eukaryotic organisms but synthesized in E. coli or other prokaryotes. As will be appreciated by one skilled in the art following the teachings herein provided, the polynucleotide molecules of the present disclosure can be expressed in a variety of prokaryotic and eukaryotic cells using regulatory sequences, vectors, and methods well established in the literature.

An ALT polypeptide produced according to the present description can be purified using a number of established methods such as affinity chromatography using anti-mALT antibodies coupled to a solid support. Fusion proteins of an antigenic tag and an ALT polypeptide can be purified using antibodies to the tag. Optionally, additional purification is achieved using conventional purification means such as liquid chromatography, gradient centrifugation, and gel electrophoresis, among others. Methods of protein purification are known in the art and can be applied to the purification of recombinant ALT polypeptide described herein.

Construction of ALT encoded fusion proteins is also contemplated. Fusion proteins typically contain additions, substitutions, or replacements of one or more contiguous amino acids of the native ALT polypeptide with amino acid(s) from a suitable fusion protein partner. Such fusion proteins are obtained using recombinant DNA techniques generally well known by one of skill in the art. Briefly, DNA molecules encoding the hybrid ALT protein of interest are prepared using generally available methods such as PCR mutagenesis, site directed mutagenesis, and/or restriction digestion and ligation. The hybrid DNA is then inserted into expression vectors and introduced into suitable host cells.

Recombinant gene expression vectors comprising a nucleic acid encoding an ALT protein of interest, or portions thereof, can be constructed in a variety of forms well-known in the art. Preferred expression vectors include plasmids and cosmids. Expression vectors include one or more fragments of murine ALT. In one embodiment of this invention, an expression vector comprises a nucleic acid encoding an ALT polynucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:5 or SEQ ID NO:6. As used herein, the phrase “operatively encode” refers to one or more protein coding regions associated with those regulatory sequences required for expression of the polypeptide encoded by the coding region. Examples of such regulatory regions including promoter binding sites, enhancer elements, ribosome binding sites, and the like. Those of ordinary skill in the art following the teachings herein provided will be able to select regulatory sequences and incorporate them into the recombinant expression vectors described herein without undue experimentation. For example, suitable regulatory sequences for use in various eukaryotic and prokaryotic systems are described in Ausubel, et al., Short Protocols in Molecular Biology, 3rd ed., John Wiley & Sons, Inc, New York, 1997, which is hereby incorporated by reference in its entirety.

Expression vectors for use with ALT typically contain regulatory sequences derived from a compatible species for expression in the desired host cell. For example, when E. coli is the host cell, the host cell population can be typically transformed using pBR322, a plasmid derived from an E. coli species. (Bolivar, et al., Gene, 2: 95, 1977). pBR322 contains genes for ampicillin (AMPR) and tetracycline resistance and thus provides easy means for identifying transformed cells.

Promoters suitable for use with prokaryotic hosts illustratively include the betalactamase and lactose promoter systems (Chang, et al., Nature, 275: 615, 1978; and Goeddel, et al., Nature, 281: 544, 1979), alkaline phosphatase, the tryptophan (trp) promoter system (Goeddel, Nucleic Acids Res., 8: 4057, 1980) and hybrid promoters such as the taq promoter (de Boer, et al., Proc. Natl. Acad. Sci. USA, 80: 21-25, 1983). Other functional bacterial promoters are also suitable. Their nucleotide sequences are generally known in the art, thereby enabling a skilled worker to ligate them to a polynucleotide which encodes the peptide of interest (Siebenlist, et al., Cell, 20: 269, 1980) using linkers or adapters to supply any required restriction sites.

In addition to prokaryotes, eukaryotic microbes such as yeast cultures can also be used as source for the regulatory sequences. Saccharomyces cerevisiae is a commonly used eukaryotic host microorganism. Suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase (Hitzeman, et al., J. Biol. Chem., 255: 2073, 1980) or other glycolytic enzymes (Hess, et al. J. Adv. Enzyme Reg. 7: 149, 1968; and Holland, Biochemistry, 17: 4900, 1978) such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degraded enzymes associated with nitrogen metabolism, metallothionine, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Yeast enhancers also are advantageously used with yeast promoters.

In another embodiment, a recombinant virus is used as the expression vector. Exemplary viruses include the adenoviruses, adeno-associated viruses, herpes viruses, vaccinia, or an RNA virus such as a retrovirus or an alphavirus. Preferably, the retroviral vector is a derivative of a murine or avian retrovirus. Preferably the alphavirus vector is derived from Sindbis or Semliki Forest Virus. All of these vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated.

By inserting one or more sequences of interest into the viral vector, along with another gene which encodes the ligand for a receptor on a specific target cell, for example, the vector is now target specific. Retroviral vectors can be made target specific by inserting, for example, a polynucleotide encoding a sugar, a glycolipid, or a protein. Preferred targeting is accomplished by using an antibody to target the retroviral vector, such as to the vicinity of a mucosal inductor site, using, for example, a mALT-specific antibody. Those of skill in the art know of, or can readily ascertain without undue experimentation, specific polynucleotide sequences which can be inserted into the retroviral genome to allow target specific delivery of the retroviral vector containing the polynucleotides of interest.

Construction of suitable vectors containing desired coding, non-coding and control sequences employ standard ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and re-ligated in the form desired to construct the plasmids required.

For example, for analysis to confirm correct sequences in plasmids constructed, the ligation mixtures can be used to transform a host cell and successful transformants selected by antibiotic resistance where appropriate. Plasmids from the transformants are prepared, analyzed by restriction and/or sequenced by, for example, the method of Messing, et al., (Nucleic Acids Res., 9: 309, 1981), the method of Maxam, et al., (Methods in Enzymology, 65: 499, 1980), or other suitable methods which are known to those skilled in the art. Size separation of cleaved fragments is performed using conventional gel electrophoresis as described, for example, by Maniatis, et al., (Molecular Cloning, pp. 133-134, 1982).

Host cells can be transformed with the expression vectors described herein and cultured in conventional nutrient media modified as is appropriate for inducing promoters, selecting transformants or amplifying genes. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan following the teachings herein provided.

In cloning murine ALT1 and murine ALT2, peptide sequences of human ALT1 and ALT2 were used as probes to search the mouse murine expressed sequence tag (EST) database using tBLASTn. A search of the mouse EST database using human ALT1 and human ALT2 peptide sequences as probes yielded several highly homologous EST clones. Of them, IMAGE clones 4195300 and 5065322 were fully sequenced and revealed the highest homology to human ALT1 and ALT2, respectively, in the entire protein-coding region. The DNA nucleotide sequences of these two clones were confirmed by sequencing analysis and are predicted to encode proteins of 496 (clone 4195300) and 522 (clone 5065322) amino acids. As shown in FIG. 1, comparison of the mouse and human peptide sequences revealed that IMAGE clone 4195300 shares about 87% identity and about 89% similarity to human ALT1, but about 70% identity and about 72% similarity to human ALT2, whereas clone 5065322 shares about 93% identity and about 95% similarity with human ALT2, but about 69% identity to human ALT1. The cDNA clone 4195300 and the clone 5065322 were thus determined to be murine ALT1 and murine ALT2, respectively. Sixty-seven percent of amino acids are identical in murine ALT1 and murine ALT2; a similar degree of conservation, about 68%, is found between human ALT1 and ALT2.

Cloning of rat ALT1 and ALT2 was achieved through bioinformatics by interrogating the closest homolog in GenBank with murine and human ALT1 and ALT2 protein sequences. The rat IMAGE clone 7113147 encodes a protein that shares 95% and 98% identity to human and murine ALT2, respectively, but 68% and 67% identity to human and murine ALT1, respectively. Thus, the cDNA clone 7113147 was determined as rat ALT2. Rat ALT1 cDNA was cloned from rat liver first-strand cDNA by PCR amplification with high-fidelity DNA polymerase using primers based rat expressed sequence tags (ESTs) which shares highest identity to murine and human ALT1 sequences. The resultant PCR fragment was cloned into TOPO cloning vector (Invitrogen) and sequenced in full. The translated protein sequence shares high identities of 88% and 97% to human and murine ALT1, respectively, but low identities of 70% and 68% to human and murine ALT2, respectively. Thus, this clone was determined as rat ALT1.

The gene expression of murine ALT1 and murine ALT2 was examined in mouse tissues by Northern analysis. Male obese mice (ob/ob), littermate control (+/?), and C57BL/6J, 6 to 8 weeks old, were obtained from Jackson Laboratory and euthanized with CO₂ according to protocol approved by Institutional Animal Care and Use Committee. Tissues were immediately frozen in liquid nitrogen until use for RNA extraction or enzyme activity assay. Total RNA was prepared with Trizol, available from Life Technologies Inc., Gaithersburg, Md., from the snap-frozen tissues. For the tissue distribution study, pooled 15 μg of total RNA from 3 to 4 mice were electrophoresed on a 1.2% agarose gel and blotted to a Nitro-plus membrane, available from Schleicher & Schuell, Dassel, Germany. The DNA probes of murine ALT1 (1.4 kb) and murine ALT2 (2.4 kb) were derived from restriction enzyme digestion of IMAGE clone 4195300 (Sal I/Not I) and clone 5065322 (Sal I/Not I), respectively. Probes were random-labeled with ³²P-dCTP, hybridization was carried out at 65° C. in Rapid-hyb buffer, available from Amersham Biosciences, Piscataway, N.J., and blots were washed twice with 0.5×SSC/1% SDS at 65° C. (stringent wash) and visualized by PhosphorImager, available from Amersham Biosciences, or x-ray film.

As shown in FIG. 2, the ≈3.3 kb murine ALT2 messenger RNA (mRNA) was expressed at high levels in muscle, liver, and white adipose tissue (WAT), at moderate levels in brain and kidney, and at a low level in heart. By contrast, the ≈1.8 kb murine ALT1 mRNA was highly expressed in liver and considerably in WAT, intestine, and colon tissue. As shown in FIG. 2 particular tissues selectively express one ALT isoenzyme over the other. For instance, murine ALT2 was significantly expressed, and murine ALT1 barely expressed, in muscle and brain tissue. In contrast, bowel tissue generally expressed only murine ALT1, and not murine ALT2.

To determine the chromosomal localization of DNA encoding murine ALT1 and murine ALT2 (gpt1 and gpt2), the corresponding cDNAs were searched against the mouse genome and localized gpt1 to murine chromosome 15D3 and gpt2 to chromosome 8C2. Both of these regions are syntenic to the chromosomal regions where human gpt1 (chromosome 8q24.3) and gpt2 (chromosome 16q12.2) reside. Full-length cDNAs of mALT1 (BC022625) and mALT2 (BC34219) were searched against the mouse genome sequence database with BLASTn, and their chromosomal localizations were determined by MapViewer.

The coding region of mALT1 cDNA was amplified by polymerase chain reaction (PCR) at 28 cycles at 94° C. for 30 seconds, 56° C. for 30 seconds, and 72° C. for 1.5 minutes, with a final extension of 7 minutes at 72° C. using the Turbo Pfu PCR system (Stratagene) with an NdeI-linked primer, p1408 5′-GGAAGATCTCATATGGCCTCACAAAGGAATGAC-3′ (nt<106-126, BC022625; SEQ ID NO:9), and a NotI;-linked primer, p1409 5′-AATGCGGCCGCTCAGGAGTACTCATGAGTGAA-3′ (1596-1576, BC022625; SEQ ID NO:10), using IMAGE clone 4195300 as a template. The resulting PCR product was digested with NdeI/NotI and subcloned into pET28a, available from Novagen, Madison, Wis., creating plasmid pET28-mALT1. The absence of mutations in the inserted murine ALT1 cDNA was verified by DNA sequence analysis. The same approach was used to clone the coding region of murine ALT2 cDNA from IMAGE clone 5065322 into pET28a by PCR using IMAGE clone 5065322 as template with primer p1405 5′-GGAAGATCTCCATGGCCCATATGCAGCGGGCAGCGGTGCTGGT-3′ (nt 128-150, BC034219; SEQ ID NO:11) and p1406 5′-AATGCGGCCGCTCATGAGTACTGCTCCAGGAA-3′ (nt 1696-1676, BC034219; SEQ ID NO:12), creating plasmid pET28-mALT2.

To express mALT1 and mALT2 proteins, plasmid pET28-mALT1, pET28-mALT2, or empty vector pET28 were used to transform competent E. coli. (Tuner DE3, available from Novagen). A fresh colony of the transformants was grown in 50 ml LB media containing 30 μg/ml kanamycin to an OD₆₀₀ of 0.7, at which time isopropyl-beta-D-thiogalactopyranoside (IPTG) was added (1 mmol, final concentration) to induce expression of the recombinant proteins. Cell pellets were harvested from 20 ml cultures before and after 4 hours of induction and were resuspended in 5 ml of TE buffer (10 mmol Tris-HCl (pH 7.4), 0.1 mmol ethylenediaminetetraacetic acid), followed by a brief sonication, 3×10 seconds, setting 3 using a Fisher 550 Sonic Dismembrator. Cell lysates were centrifuged at 10,000 g for 15 minutes at 4° C., and supernatants were analyzed immediately for enzyme activity and protein analysis.

Soluble fractions of cell lysates were assayed for ALT activity and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis. As shown in FIG. 3A, under induction of IPTG, significant ALT activity was observed in cell lysates from bacteria transformed with pET28-mALT1 (2.62 units/mg protein) and pET28-mALT2 (0.72 units/mg protein), compared to empty vector control (0.19 units/mg protein). Accordingly, as shown in FIG. 3B, protein bands at approximate molecular weights (MW) of 58 kd and 62 kd were clearly visible in bacterial cell pellets after IPTG induction, corresponding to murine ALT1 (calculated MW=55 kd) and murine ALT2 (calculated MW=58 kd). It should be noted that murine ALT activities detected in the above cell lysates do not reflect the specific activity of the murine ALT isoenzymes, as most of the recombinant proteins were expressed in insoluble fraction of inclusion body, and, therefore, the actual amount of ALT in the cell lysates was not known. Nevertheless, these data confirm that murine ALT1 and ALT2 cDNAs encode functional murine ALT.

The ALT activity of the bacterially expressed recombinant murine ALT proteins was confirmed using a GPT Optimized Alanine Aminotransferase kit, available from Sigma Diagnostics (catalog no. DG159-K), St. Louis, Mo., according to manufacturer instructions. Briefly, 0.5 ml of cell lysate was incubated with a 2.5 ml mixture of reagent A and B containing L-alanine, nicotinamide adenine dinucleotide, Lactate Dehydrogenase, and 2-oxoglutarate at 25° C. Absorbance at 340 nm was recorded at 1, 2, and 3 minutes after incubation. The slope of absorbance decrease is proportional to ALT activity. Protein concentration of cell lysates were determined by Coomassie Brilliant Blue G250 (BioRad) using bovine serum albumin as a standard. Final ALT activities were corrected by protein concentration of cell lysates. One unit of ALT activity was defined as the amount of enzyme that catalyzes the formation of 1 μmol/liter of nicotinamide adenine dinucleotide per minute at 25° C.

To demonstrate hepatic ALT and aspartate aminotransferase (AST) activity, a piece of snap-frozen liver (50-60 mg) was thawed on ice and then minced and homogenized in 19 volumes of TE buffer (wt/vol) with Dounce homogenizer (40 times). The resulting homogenate was further sonicated (3×10 seconds, setting 4, using a Fisher 550 Sonic Dismembrator) followed by centrifugation at 10,000 rpm for 15 minutes at 4° C. The supernatant was assayed for hepatic ALT using an L-type GPT J2 kit, available from Wako Chemicals, Osaka, Japan, according to the manufacturer's instructions. AST activity was measured with an AST/GOT Liqui-UV kit, available from Stanbio Laboratories, Boerne, Tex., according to the manufacturer's instructions.

Murine ALT2 gene expression is specifically induced in fatty liver. The distinctive tissue distribution patterns of murine ALT1 and ALT2 mRNAs are likely due to a difference in their gene regulation. Gene expression differences were examined in fatty livers of obese mice (ob/ob). FIGS. 4A-C demonstrate the increased mALT2 gene expression in fatty liver. FIGS. 4A and 4B are duplicate blots containing 15 μg of total RNA extracted from fatty liver of obese (ob/ob) and lean (+/?) mice blotted with ³²P labeled mALT1 or mALT2 DNA probe. Hybridization signals were visualized and quantitated by PhosphorImager. In FIGS. 4A and 4B, RNA loading from one of the duplicate gels is shown in lower blot. FIG. 4C shows data expressed as mean ±SD (n=3). *P<0.05 is considered statistically significant. As shown in FIGS. 4A-C, compared to the normal liver of the lean mice control (+/?), the expression of murine ALT2 mRNA was elevated about 1-fold, but that of murine ALT1 remained unchanged. Furthermore, a significant elevation (30%, P<0.01) of murine ALT enzymatic activity was observed in fatty liver relative to normal liver. The data indicates that murine ALT2 induction is most generally responsible for the increased murine ALT activity in fatty liver. Interestingly, as shown in FIG. 5, AST activity was barely increased in fatty liver (5%, P=0.5) compared with normal liver.

Thus the invention provides molecular cloning of animal homologues of human ALT1 and ALT2. ALT is an important intermediary enzyme involved in the metabolism of amino acids, glucose, and possibly fatty acids and is well known for its use as a surrogate marker for liver damage in clinical diagnostics. In addition to the dissimilarity of the peptide sequences of murine ALT1 and murine ALT2, the mouse genes reside on separate chromosomes and have distinct tissue distributions and possibly cellular localizations. The murine ALT isoenzymes behave discordantly in various clinical conditions. In other words, under certain clinical conditions, one isoenzyme may be elevated but not the other, or vice versa. By virtue of this feature, individual murine ALT isoenzymes can be better diagnostic markers than a total murine ALT activity. Similarly, individual rat ALT isoenzymes can be better diagnostic markers than a total rat ALT activity.

ALT activities are present in many tissues, including liver, heart, kidney, muscle, brain, and adipose tissue in rodents. Northern blot data indicate one or both of the murine ALT genes are expressed in the tissues where ALT activity has been observed. Murine ALT1 is mainly expressed in liver and bowels, whereas murine ALT2 is highly expressed in muscle, liver, fat, and kidney, a tissue pattern reminiscent of human ALT1 and ALT2 tissue distribution. The conservation among rat, murine and human ALT isoenzymes in protein sequence, gene localization, and tissue distribution forms a basis for using the rat and/or mouse as a model for exploring the diagnostic value of ALT isoenzymes.

ALT and AST activity levels have been used in clinic diagnostics for many years. Elevation of these two enzyme activities in serum are regarded as evidence of liver damage, as in viral hepatitis, NASH, or drug hepatotoxicity. However, the mechanism for the serum ALT increase has not been well understood and has been thought to be caused by “leakage” of the cellular enzyme into the systemic circulation. Moreover, which ALT isoenzyme is responsible for the serum elevation has not been known because the current ALT assay measures total catalytic activity of ALT, presumably the combined activity of ALT1 and ALT2.

Molecular cloning of ALT isoenzymes in rat and mice provides a means to study the underlying mechanism(s) as well as an interpretation of clinical ALT observations. For example, ALT elevation in muscle disease may be due to a “leak” of ALT, presumably ALT2, from muscle, where ALT2, but not ALT1, is abundantly expressed. Similarly, a specific ALT isoenzyme may be induced in a given clinical condition.

The hepatic murine ALT1 and murine ALT2 gene expression were examined in obese mice because hepatic steatosis is associated with this genetically obese model. Indeed, murine ALT2, but not murine ALT1, gene expression is specifically induced. Furthermore, total murine ALT enzymatic activity is increased by 30% in fatty liver over nonfatty liver, suggesting that murine ALT2 may be primarily responsible for the increased serum ALT activity in liver steatosis. Interestingly, AST activity remains unchanged in the same condition. These animal findings are in agreement with clinical observations in which serum ALT is generally increased to a greater extent than AST in patients with liver steatosis.

Additionally, the ALT isoenzymes may be present in different cellular compartments, which can also be utilized for diagnostic purposes: the release of a given ALT isoenzyme into circulation reflects the nature of the liver damage. It has been shown that serum mitochondrial AST content is specifically increased in patients treated with halothane, and suggested that this AST isoenzyme is a sensitive marker for halothane-induced hepatic injury. Both cytosolic and mitochondrial murine and rat ALT activities were found in liver, kidney, and skeletal and cardiac muscles. At present, which ALT isoenzyme is cytosolic or mitochondrial is not certainly clear. ALT isoenzyme specific antibodies help to elucidate the cellular localization of ALT isoenzymes and their changes in disease states.

In certain embodiments of the present invention, ALT isoform-specific antibody is required for establishment of isoform-specific detection, such as by enzyme-linked immunoabsorbant assay (ELISA). For this purpose, a recombinant ALT1 polypeptide and/or a recombinant ALT2 polypeptide is generated in bacteria and purified to homogeniety. About 2 mg of the purified protein is used to immunize mice for generating antibody specific for murine ALT or, alternatively, to immunize rats for generating antibody specific for rat ALT. As a result, a monoclonal hybridoma against a isoform of an ALT polypeptide of the present invention is determined by determining binding specificity to said ALT polypeptide. One such method is Western blot analysis in which about 20 ng of ALT2, of ALT1, and of bovine serum albumin are load onto an SDS-PAGE gel, electrophoresised, and blotted to PVDF membrane, which is incubated with cell culture media of the indicated hybridoma cells (1:100 dilution) and visualized by chemiluminescence. Cross-reaction of the antibody produced by the hyridoma cell identified above to the other isoform is also determined. The identified isoform-specific antibody is employed in the methods of the present invention, such as an ALT isoform-specific ELISA.

Differences in ALT isoenzyme in tissue distribution, gene regulation, and possible cellular localization suggest that the ability to measure ALT isoenzyme-specific activity levels is a significant improvement over measurement of total ALT activity in clinical diagnostics. The cloning of murine and rattus homologues of human ALT isoenzymes provides a novel tool for clinical applications of ALT isoenzymes as molecular markers for nonalcoholic fatty liver diseases as well as other clinical conditions.

Data herein are generally presented as mean ±standard deviation (SD). Statistical significance was determined by Student unpaired t test. P value less than 0.05 was considered significant.

While the embodiments of the invention described herein are presently preferred, various modifications and improvements can be made without departing from the spirit and scope of the invention. The scope of the invention is indicated by the appended claims, and all changes that fall within the meaning and range of equivalents are intended to be embraced therein. 

1. A voltage generator device comprising: a voltage generating portion that receives an input voltage and generates a target voltage; an observing portion that observes an operating condition of the voltage generating portion; and a control portion which causes the voltage generating portion to maintain a voltage generating operation even if the operating condition observed by the observing portion is within a first region that is apart from a normal region, and which causes the voltage generating portion to stop the voltage generating operation if the operating condition observed is within a second region that is further apart from the normal region than the first region is, wherein the voltage generator device is capable to attain a voltage compensation by raising an output voltage when a battery voltage decreases at the time of restart of an engine after an idle stop, wherein, if an output current exceeds a first value of current, the output voltage is reduced, or if the output voltage exceeds a first value of voltage, a switching operation of the voltage generating portion is intermittently performed.
 2. The voltage generator device according to claim 1, wherein the operating condition is within the first region if a current through the voltage generating portion is greater than a first value of current and is less than or equal to a second value of current, and the operating condition is within the second region if the current through the voltage generating portion is greater than the second value of current.
 3. The voltage generator device according to claim 2, wherein the control portion reduces a target value of voltage output by the voltage generating portion if a value of current through the voltage generating portion increases provided that the operating condition is within the first region.
 4. The voltage generator device according to claim 1, wherein the operating condition is within the first region if a voltage output by the voltage generating portion is greater than a first value of voltage and is less than or equal to a second value of voltage, and the operating condition is within the second region if the voltage output by the voltage generating portion is greater than the second value of voltage.
 5. The voltage generator device according to claim 4, wherein the observing portion includes a voltage detecting circuit (14) that detects the first value of voltage, and an overvoltage detecting circuit that detects the second value of voltage, and wherein the control portion performs on the voltage generating portion (11) a feedback control of setting an output of the voltage generating portion at the target voltage in accordance with an output of the voltage detecting circuit, and stops the feedback control in accordance with an output of the overvoltage detecting circuit and prohibits the voltage generating portion from performing the voltage generating operation.
 6. A motor vehicle comprising: an electricity storage portion; a voltage generator device that compensates for a fall of an output voltage of the electricity storage portion, and an automatic engine stop control device that automatically controls stopping and starting of an engine, wherein the voltage generator device includes a voltage generating portion that receives an input voltage and generates a target voltage, an observing portion that observes an operating condition of the voltage generating portion, and a control portion which causes the voltage generating portion to maintain a voltage generating operation even if the operating condition observed by the observing portion is within a first region that is apart from a normal region, and which causes the voltage generating portion to stop the voltage generating operation if the operating condition observed is within a second region that is further apart from the normal region than the first region is, and wherein the automatic engine stop control device prohibits an automatic stop of the engine if it is detected that the operating condition is within the first region, and wherein the voltage generator device is capable to attain a voltage compensation by raising an output voltage when a battery voltage decreases at the time of restart of an engine after an idle stop, wherein, if an output current exceeds a first value of current, the output voltage is reduced, or, if the output voltage exceeds a first value of voltage, a switching operation of the voltage generating portion is intermittently performed.
 7. A control method for a voltage generator device comprising the steps of: observing an operating condition of the voltage generating portion, which receives an input voltage and generates a target voltage, and causing the voltage generating portion to maintain a voltage generating operation even if the operating condition is within a first region that is apart from a normal region; and causing the voltage generating portion to stop the voltage generating operation if the operating condition observed is within a second region that is further apart from the normal region than the first region is, wherein the voltage generator device attains a voltage compensation by raising an output voltage when a battery voltage decreases at the time of restart of an engine after an idle stop, wherein, if an output current exceeds a first value of current, the output voltage is reduced, or, if the output voltage exceeds a first value of voltage, a switching operation of the voltage generating portion is intermittently performed.
 8. The control method for the voltage generator device according to claim 7, wherein the operating condition is within the first region if a current through the voltage generating portion is greater than a first value of current and is less than or equal to a second value of current, and the operating condition is within the second region if the current through the voltage generating portion is greater than the second value of current.
 9. The control method for the voltage generator device according to claim 8, wherein a target value of voltage output by the voltage generating portion is reduced if a value of current through the voltage generating portion increases provided that the operating condition is within the first region.
 10. The control method for the voltage generator device according to claim 7, wherein the operating condition is within the first region if a voltage output by the voltage generating portion is greater than a first value of voltage and is less than or equal to a second value of voltage, and the operating condition is within the second region if the voltage output by the voltage generating portion is greater than the second value of voltage.
 11. The control method for the voltage generator device according to claim 10, wherein the voltage generator device includes a voltage detecting circuit that detects the first value of voltage, and an overvoltage detecting circuit that detects the second value of voltage, and wherein the control method further comprises the step of performing on the voltage generating portion a feedback control of setting an output of the voltage generating portion at the target voltage in accordance with an output of the voltage detecting circuit, and the step of stopping the feedback control in accordance with an output of the overvoltage detecting circuit (15) and prohibiting the voltage generating portion from performing an operation.
 12. A control method for a motor vehicle comprising the steps of: observing an operating condition of the voltage generator device, which compensates for a change in an output voltage of an electricity storage device, and causing the voltage generator device to maintain a voltage generating operation even if the operating condition is within a first region that is apart from a normal region; controlling stopping and starting of an engine in accordance with a state of the motor vehicle if the operating condition is within the normal region; and prohibiting an automatic stop of the engine if it is detected that the operating condition is within the first region, wherein the voltage generator device attains a voltage compensation by raising an output voltage when a battery voltage decreases at the time of restart of an engine after an idle stop, wherein, if an output current exceeds a first value of current, the output voltage is reduced, or, if the output voltage exceeds a first value of voltage, a switching operation of the voltage generating portion is intermittently performed.
 13. A computer-readable recording medium in which a program for causing a computer to execute the control method for the voltage generator device according to claim 7 is recorded.
 14. A computer-readable recording medium in which a program for causing a computer to execute the control method for the motor vehicle according to claim 12 is recorded. 